Section Arrow
ARVN.NASDAQ
- Arvinas
Quotes are at least 15-min delayed:2024/05/16 13:38 EDT
Last
 33.175
+0.845 (+2.61%)
Day High 
34.67 
Prev. Close
32.33 
1-M High
35.865 
Volume 
714.37K 
Bid
33.12
Ask
33.23
Day Low
32.83 
Open
33.88 
1-M Low
30.91 
Market Cap 
2.21B 
Currency USD 
P/E -- 
%Yield
10-SMA 32.29 
20-SMA 32.67 
50-SMA 37.62 
52-W High 53.08 
52-W Low 13.57 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-6.05/-4.42
Enterprise Value
2.21B
Balance Sheet
Book Value Per Share
8.91
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
78.50M
Operating Revenue Per Share
2.33
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.1042+0.0265+34.11%-- 
DNAGinkgo Bioworks Holdings0.8376-0.0015-0.18%-- 
NBYNovaBay Pharmaceuticals0.125+0.0205+19.62%-- 
JAGXJaguar Health0.2827+0.0276+10.82%-- 
NVAXNovavax13.3197+0.4197+3.25%-- 
Quotes are at least 15-min delayed:2024/05/16 13:38 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.